MedTrace Logo

Aerosol Cyclosporine for Prevention of Lung Rejection

NCT00268515 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2016-05-13

No results posted yet for this study

Summary

To evaluate the efficacy of aerosolized cyclosporine given in addition to the standard oral immunosuppressive drug regimen, in preventing acute rejection immediately after lung transplantation

Conditions

  • Lung Diseases

Interventions

DRUG

cyclosporine

DRUG

tacrolimus

DRUG

prednisone

DRUG

azathioprine

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    lead NIH

Principal Investigators

  • Aldo Iacono · University of Pittsburgh

Study Design

Purpose
PREVENTION
Masking
DOUBLE

Eligibility

Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-04-30
Completion
2003-03-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00268515 on ClinicalTrials.gov